{"id":"abrocitinib-200-mg","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Live vaccines","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Bacillus Calmette-Guérin (BCG) vaccine","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Other vaccines","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Interferon-alpha","action":"Monitor","effect":"Increased risk of hepatotoxicity"},{"drug":"Interferon-beta","action":"Monitor","effect":"Increased risk of hepatotoxicity"},{"drug":"Interferon-gamma","action":"Monitor","effect":"Increased risk of hepatotoxicity"},{"drug":"Other immunosuppressants","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Methotrexate","action":"Monitor","effect":"Increased risk of hepatotoxicity"},{"drug":"Azathioprine","action":"Monitor","effect":"Increased risk of hepatotoxicity"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased risk of hepatotoxicity"},{"drug":"Tacrolimus","action":"Monitor","effect":"Increased risk of hepatotoxicity"},{"drug":"Sirolimus","action":"Monitor","effect":"Increased risk of hepatotoxicity"},{"drug":"Everolimus","action":"Monitor","effect":"Increased risk of hepatotoxicity"},{"drug":"Rapamycin","action":"Monitor","effect":"Increased risk of hepatotoxicity"},{"drug":"Other immunosuppressants","action":"Monitor","effect":"Increased risk of infections"}],"commonSideEffects":[],"contraindications":["Do not start CIBINQO if you: - are under 12 years of age\n- intend to use it for a condition for which it was not prescribed \n- have any kind of infection unless your healthcare provider tells you it is okay \n- have any signs and symptoms of blood clots \n- have lymphocyte, neutrophil, red blood cell, or platelet counts that are too low \n- take medicines that prevent blood clots (antiplatelet medicines), except for low-dose aspirin up to a dose of 81 mg each day during the first 3 months of CIBINQO treatment \n- are taking certain other medicines\n- are breastfeeding or plan to breastfeed\n- have severe kidney problems\n- have severe liver problems\n- recently received a live vaccine"],"specialPopulations":{"Pregnancy":"Cibinqo is contraindicated during pregnancy (see section 4.3). There are no or limited amount of data on the use of abrocitinib in pregnant women. Studies in animals have shown reproductive toxicity. Abrocitinib has been shown to cause embryo-foetal lethality in pregnant rats and rabbits, skeletal variations in the foetuses of pregnant rats and rabbits, and to affect parturition and peri/postnatal development in rats.","Geriatric use":"For patients 65 years of age and older, the recommended dose is 100 mg once daily (see section 4.4).","Paediatric use":"The safety and efficacy of Cibinqo in children under 12 years of age have not yet been established. The pharmacokinetics of abrocitinib in children and adolescents have not been studied in clinical trials.","Renal impairment":"adjustment is required in patients with mild renal impairment, i.e. estimated glomerular filtration rate (eGFR) greater than or equal to 60 mL/min per 1.73 m²","Hepatic impairment":"No dose adjustment is required in patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment. Abrocitinib is contraindicated to patients with severe (Child Pugh C) hepatic impairment (see section 4.3). Patients with mild (Child Pugh A) and moderate (Child Pugh B) hepatic impairment had approximately 4% decrease and 15% increase in active moiety AUCinf, respectively, compared to patients with normal hepatic function."}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=abrocitinib-200-mg","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:41:33.290861+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:41:39.113366+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:41:33.362667+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=abrocitinib-200-mg","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:41:39.519199+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Tyrosine-protein kinase JAK1 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:41:41.245324+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3655081/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:41:40.902308+00:00"}},"allNames":"abrocitinib 200 mg","offLabel":[],"timeline":[],"aiSummary":"Abrocitinib is a small molecule inhibitor of the tyrosine-protein kinase JAK1. It is being studied for various conditions, including Chronic Spontaneous Urticaria, Hidradenitis Suppurativa, Psoriasis, Atopic Dermatitis, and has also been studied in a Phase 1 trial to assess its effect on rosuvastatin pharmacokinetics in healthy participants.","brandName":"Abrocitinib 200 mg","ecosystem":[],"isGeneric":true,"mechanism":{"target":"JAK1","novelty":"best-in-class","modality":"small molecule","drugClass":"JAK inhibitor","explanation":"","oneSentence":"","technicalDetail":"Abrocitinib selectively inhibits the JAK1 enzyme with a high degree of specificity, reducing the production of pro-inflammatory cytokines such as IL-4, IL-13, and TNF-alpha. This leads to a decrease in the inflammatory response and an improvement in skin clearance. The drug's mechanism of action is supported by clinical trials, which have demonstrated its efficacy in treating moderate to severe atopic dermatitis."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"revenueYear":2025,"annualCostUS":"$80,000/yr","annualRevenue":284,"genericStatus":"Generic — off-patent","revenueSource":"SEC 8-K Pfizer (2026-02-03)","currentRevenue":"$21.2B","revenueCurrency":"USD","peakSalesEstimate":"$21.2B","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T10:48:50.281182","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=abrocitinib-200-mg","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=abrocitinib-200-mg","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:41:42.576891+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Dupilumab","company":"Unknown","advantage":"Higher response rate at 16 weeks (61.5% and 82.1%) compared to Abrocitinib"},{"name":"Tralokinumab","company":"Unknown","advantage":"Higher response rate at 16 weeks (49.3% and 82.1%) compared to Abrocitinib"},{"name":"Baricitinib 2mg","company":"Unknown","advantage":"Lower cost per treatment compared to Abrocitinib"},{"name":"Baricitinib 4mg","company":"Unknown","advantage":"Lower cost per treatment compared to Abrocitinib"},{"name":"Upadacitinib 15mg","company":"Unknown","advantage":"Higher response rate at 16 weeks (67.7%) compared to Abrocitinib"},{"name":"Upadacitinib 30mg","company":"Unknown","advantage":"Higher response rate at 16 weeks (compared to Abrocitinib, but exact percentage not specified)"}],"genericName":"abrocitinib-200-mg","indications":{"approved":[{"name":"Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06283550","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy","status":"COMPLETED","sponsor":"Innovaderm Research Inc.","startDate":"2024-05-31","conditions":"Chronic Hand Eczema","enrollment":82},{"nctId":"NCT07242638","phase":"PHASE2","title":"Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-01-12","conditions":"Atopic Dermatitis, Alopecia Areata","enrollment":56},{"nctId":"NCT03422822","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-03-08","conditions":"Dermatitis, Atopic","enrollment":3166},{"nctId":"NCT05743244","phase":"PHASE2","title":"Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2023-10-19","conditions":"Diabetes Mellitus, Type 1","enrollment":78},{"nctId":"NCT05696795","phase":"PHASE2","title":"Janus Kinase Inhibition in Sarcoidosis","status":"COMPLETED","sponsor":"Yale University","startDate":"2023-06-01","conditions":"Sarcoidosis","enrollment":10},{"nctId":"NCT05650736","phase":"PHASE2","title":"Janus Kinase Inhibition in Granuloma Annulare","status":"ACTIVE_NOT_RECRUITING","sponsor":"William Damsky","startDate":"2023-10-27","conditions":"Granuloma Annulare","enrollment":10},{"nctId":"NCT04903093","phase":"PHASE1","title":"A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-06-04","conditions":"Healthy Volunteers","enrollment":19},{"nctId":"NCT05375929","phase":"PHASE3","title":"A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-07-16","conditions":"Atopic Dermatitis","enrollment":200},{"nctId":"NCT05067439","phase":"PHASE1","title":"A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-10-21","conditions":"Healthy Participants","enrollment":26},{"nctId":"NCT05038982","phase":"PHASE2","title":"Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2021-09-09","conditions":"Prurigo Nodularis, Pruritus, Chronic Pruritus","enrollment":20},{"nctId":"NCT04345367","phase":"PHASE3","title":"Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-11","conditions":"Atopic Dermatitis","enrollment":727}],"_emaApprovals":[{"date":"","name":"Abrocitinib 200 mg","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":true,"chemblId":"CHEMBL3655081","moleculeType":"Small molecule","molecularWeight":"323.42"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL3655081"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":66,"therapeuticAreas":["Immunology"],"_revenueScrapedAt":"2026-04-01 09:48:50.313664+00","biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb 23","pmid":"41729754","title":"Efficacy of Abrocitinib and Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Using Treat-to-Target Goals Recommended by Experts in China.","journal":"International archives of allergy and immunology"},{"date":"2026 Dec","pmid":"41503869","title":"Dose-dependent effectiveness and patient-reported outcomes with JAK1 inhibitors in atopic dermatitis: a 36-week multicenter real-world cohort.","journal":"The Journal of dermatological treatment"},{"date":"2026 Jan 5","pmid":"41489415","title":"Upadacitinib Leads in Efficacy: A Bayesian Network Meta-Analysis of Four JAK Inhibitors in Moderate-To-Severe Atopic Dermatitis.","journal":"International journal of dermatology"},{"date":"2025 Dec 26","pmid":"41454520","title":"Efficacy and Safety of Abrocitinib and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis.","journal":"Journal of cutaneous medicine and surgery"},{"date":"2026 Mar 26","pmid":"41270045","title":"Comparative effectiveness and safety of upadacitinib, abrocitinib and dupilumab in treatment-resistant prurigo nodularis.","journal":"Clinical and experimental dermatology"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"approved","companyName":"Pfizer","companyId":"pfizer","modality":"small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":9,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":6,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:41:42.576891+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}